[Skip to Content]
[Skip to Content Landing]
Article
January 5, 1957

ADENOVIRUS (RI-APC-ARD) VACCINE FOR PREVENTION OF ACUTE RESPIRATORY ILLNESS2. FIELD EVALUATION

Author Affiliations

Washington, D. C.

From the Department of Epidemiology and the Department of Respiratory diseases, Walter Reed Army Institute of Research. Dr. Stallones is now at the School of Public Health, University of California, Berkeley.

JAMA. 1957;163(1):9-15. doi:10.1001/jama.1957.02970360011003
Abstract

• A formalin-killed adenovirus vaccine was administered to a test group A of 311 infantry recruits, and the subsequent record of this group as to hospitalization and serologic findings was compared with that of a contratest group B of 313 men who received injections of a placebo. The vaccine caused no untoward reactions. Its effect became manifest within a week after the initial injection, and during the period including the second to the fifth week there was only one case of serologically positive adenovirus disease requiring hospitalization in group A as compared with 61 cases in group B. Blood specimens were collected from all subjects at the time of the initial injection and three and seven weeks after it, for determination of the adenovirus complement-fixing antibody titers. Group A showed an increase in titer from 1.4 to 6.3 by the third week, while group B followed a different course, with the titer (geometric mean) rising to a level of 11 by the seventh week. The effect on frequency of hospitalization indicated that the vaccine has potential value in military populations.

×